Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Office Takes First Steps Toward Implementing Bilski Decision

Executive Summary

While the Supreme Court's ruling in Bilski v. Kappos left several questions unanswered, the U.S. Patent and Trademark Office is prepared to implement the decision

You may also be interested in...



Supreme Court Suggests Setting Limits On Business Method Patents

In case that could have implications for patents on medical processes, justices question the Federal Circuit's application of the "machine-or-transformation" standard in Bilski v. Kappos.

Biotech Patents Vulnerable? Court Ruling May Have Ripple Effect For Life Sciences Industry

Federal Circuit’s Bilski ruling could make some biotechnology patents vulnerable to infringement, industry group says.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS052401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel